SHEL.UK

3,308

+0.3%↑

BP

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

BP

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

BP

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

BP

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

BP

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

Search

Smith & Nephew PLC

Fermé

1,157 -2.94

Résumé

Variation du prix de l'action

24h

Actuel

Min

1142

Max

1177.5

Chiffres clés

By Trading Economics

Revenu

47M

342M

Ventes

318M

3.3B

P/E

Moyenne du Secteur

23.774

77.607

BPA

0.429

Rendement du dividende

3.1

Marge bénéficiaire

10.36

Employés

16,988

EBITDA

162M

886M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+20.26% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.10%

3.49%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-391M

11B

Ouverture précédente

1159.94

Clôture précédente

1157

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 avr. 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 avr. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 avr. 2026, 22:33 UTC

Résultats

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 avr. 2026, 22:17 UTC

Résultats

PLS Executed Offtake Agreement With Ronbay

23 avr. 2026, 22:17 UTC

Résultats

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 avr. 2026, 22:16 UTC

Résultats

PLS Commences Commissioning of Midstream Demonstration Plant

23 avr. 2026, 22:15 UTC

Résultats

PLS Group Reaffirms FY26 Guidance for All Metrics

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 avr. 2026, 22:13 UTC

Résultats

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:11 UTC

Résultats

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 avr. 2026, 22:10 UTC

Résultats

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 avr. 2026, 22:09 UTC

Résultats

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 avr. 2026, 22:08 UTC

Résultats

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 avr. 2026, 22:04 UTC

Résultats

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 avr. 2026, 21:56 UTC

Market Talk
Résultats

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 avr. 2026, 21:27 UTC

Résultats

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 avr. 2026, 21:25 UTC

Résultats

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 avr. 2026, 21:24 UTC

Résultats

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 avr. 2026, 21:24 UTC

Résultats

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 avr. 2026, 21:21 UTC

Résultats

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 avr. 2026, 21:21 UTC

Résultats

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparaison

Variation de prix

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

20.26% hausse

Prévisions sur 12 Mois

Moyen 1,460.57 GBX  20.26%

Haut 1,700 GBX

Bas 1,300 GBX

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

4

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat